Heart Rate, Life Expectancy and the Cardiovascular System: Therapeutic Considerations

Cardiology (Switzerland)

Volumn 132, Issue 4, 2015, Pages 199-212

  Boudoulas, Konstantinos Dean ^a   Borer, Jeffrey S ^b   Boudoulas, Harisios ^a,c,d  

^a OHIO STATE UNIVERSITY   (United States)

^b SUNY DOWNSTATE MEDICAL CENTER   (United States)

^c BIOMEDICAL RESEARCH FOUNDATION   (Greece)

^d ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

Cardiovascular system; Heart rate; Life expectancy

Indexed keywords

ALPRENOLOL; ANTIDIABETIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IVABRADINE; METOPROLOL; MINERALOCORTICOID ANTAGONIST; NITRIC ACID DERIVATIVE; OXPRENOLOL; PINDOLOL; PLACEBO; PRACTOLOL; PROPRANOLOL; SOTALOL; TIMOLOL; TRANDOLAPRIL; VERAPAMIL;

ANTIHYPERTENSIVE THERAPY; AORTA; AORTA PRESSURE; ARTERIAL STIFFNESS; ARTERY; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR SYSTEM; CAROTID ARTERY; CLINICAL TRIAL (TOPIC); CORONARY ARTERY BLOOD FLOW; CORONARY ARTERY DISEASE; ENDOTHELIAL DYSFUNCTION; HEART; HEART FAILURE; HEART INFARCTION; HEART MUSCLE OXYGEN CONSUMPTION; HEART RATE; HEART VENTRICLE WORK; HUMAN; HYPERTENSION; INFLAMMATION; LIFE EXPECTANCY; METABOLIC RATE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RADIAL ARTERY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESTING HEART RATE; RISK FACTOR; SURVIVAL RATE; VASCULAR ENDOTHELIUM; ANIMAL; ARTERIAL PRESSURE; CARDIOVASCULAR DISEASES; MORTALITY; MOUSE; PATHOPHYSIOLOGY; PHYSIOLOGY; RAT;

ANIMALS; ARTERIAL PRESSURE; CARDIOVASCULAR DISEASES; HEART; HEART RATE; HUMANS; LIFE EXPECTANCY; MICE; RATS; RISK FACTORS;

EID: 84940665701     PISSN: 00086312     EISSN: 14219751     Source Type: Journal    
DOI: 10.1159/000435947     Document Type: Article

References (75)

1. Levine HJ: Rest heart rate and life expectancy. J Am Coll Cardiol 1997; 30: 1104-1106.
2. Hulbert AJ, Ramplona R, Buffenstein R, Buttemer WA: Life and death: Metabolic rate, membrane composition, and life span of animals. Physiol Rev 2007; 87: 1175-1213.
3. DiFrancesco D, Borer JS: The funny current: cellular basis for the control of heart rate. Drugs 2007; 67: 15-24.
4. Olshansky B, Sullivan RM: Inappropriate sinus tachycardia. J Am Coll Cardiol 2013; 61: 793-801.
5. Eigelsheim M, Newton-Cheh C, Sotoodehnia, et al: Genome-wide association analysis identifies multiple loci related to resting heart rate. Hum Mol Genet 2010; 19: 3385-3394.
6. Vaanholt LM, Daan S, Schubert KA, Visser GH: Metabolism and aging: effects of cold exposure on metabolic rate, body composition, and longevity in mice. Physiol Biochem Zool 2009; 82: 314-324.
7. Boudoulas H, Rittgers SE, Lewis RP, Leier CV, Weissler AM: Changes in diastolic time with various pharmacologic agents: implication for myocardial perfusion. Circulation 1979; 60: 164-169.
8. Obdahl A, Venkatesh BA, Fernandes VRS, Wu CO, Nasir K, Choi EY, Almeida AL, Rosen B, Carvalho B, Edvardsen T, Bluemke DA, Lima JAC: Resting heart rate as predictor for left ventricular dysfunction and heart failure. MESA (Multiethnic Study of Atherosclerosis). J Am Coll Cardiol 2014; 63: 1182-1189.
9. Levy R, White PD, Stroud WD, Cha BG: Transient tachycardia. Prognostic significance alone and in association with transient hypertension. JAMA 1945; 129: 585-588.
10. Boudoulas H, Leier CV: Clinical perspective: myocardial perfusion pressure in the age of afterload reduction. ACC Curr J Rev 2000; 9: 27-29.
11. Boudoulas H, Karayannacos PE, Kien N, Lewis RP, Kakos GS, Leir CV, Vasco JS: Noninvasive method of estimating relative subendocardial flow employing diastolic time; in Dietrich E (ed): Noninvasive Assessment of the Cardiovascular System. Littleton, John Wright-PSG Inc, 1982, pp 211-217.
12. Boudoulas H: Diastolic time: the forgotten dynamic factor. Implications for myocardial perfusion. Acta Cardiol 1991; 46: 61-71.
13. Boudoulas H: Diastolic time: implications for myocardial perfusion and ventricular filling. Hell J Cardiol 1991; 32: 400-409.
14. Boudoulas H, Dervenagas S, Fulkerson PK, Bush CA, Lewis RP: Effect of heart rate on diastolic time and left ventricular performance in patients with atrial fibrillation; in: Noninvasive Cardiovascular Diagnosis, ed 2. Littleton, Mass PSG Inc, 1981, pp 433-445.
15. Ling L, Khammy O, Byne M, Amirahmadi F, Foster A, Li G, Zhang L, Remedios C, Chen C, Kaye DM: Irregular rhythm adversely influences calcium handling in ventricular myocardium. Circ Heart Fail 2012; 5: 786-793.
16. Boudoulas KD, Vlachopoulos C, Raman SV, Sparkas EA, Triposkiadis F, Stefanadis C, Boudoulas H: Aortic function: from the research laboratory to the clinic. Cardiology 2012; 121: 31-42.
17. Boudoulas H, Stefanadis C: The Aorta: Structure, Function, Dysfunction, and Diseases. New York, Informa Healthcare, 2009.
18. Boudoulas H, Toutouzas P, Wooley CF: Functional Abnormalities of the Aorta. Futura, Armonk, 1996.
19. Nichols WW, O'Rourke MF, Vlachopoulos C (eds): McDonald's Blood Flow in Arteries: Theoretical, Experimental and Clinical Principles, ed 6. London, Hoder Arnold, 2011.
20. Thorin E, Thorin-Trescases N: Vascular endothelial aging, heartbeat after heartbeat. Cardiovasc Res 2009; 84: 24-32.
21. Custodis F, Schirmer SH, Baumhakel M, Heusch G, Bohm M, Laufs U: Vascular pathophysiology in response to increased heart rate. J Am Coll Cardiol 2010; 56: 1973-1983.
22. Giannattasio C, Vincenti A, Failla M, Capta A, Ciro A, De Ceglia S, Getile G, Brambilla R, Mancia G: Effects of heart rate changes on arterial distensibility in humans. Hypertension 2003; 42: 253-256.
23. Wilkinson IB, MacCallum H, Flint L, Cockcroft JR, Newby D, Webb DJ: The influence of heart rate on augmentation index and central arterial pressure in humans. J Physiol 2000; 525: 263-270.
24. Tartiere-Kesri L, Tartieri JM, Logeart D, Bwauvais F, Solal C: Increased proximal arterial stiffness and cardiac response with moderate exercise in patients with heart failure and preserved ejection fraction. J Am Coll Cardiol 2012; 59: 455-461.
25. Borlaud BA: Heart rate reduction. It is not just for ventricles anymore. J Am Coll Cardiol 2013; 62: 1986-1987.
26. Williams B, Lacy PS, Thom SM, Cruickshank K, Stanton A, Collier D, Hughes AD, Thuster A, O'Rourke M: Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes. Principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation 2006; 113: 1213-1225.
27. Benetos A, Adamopoulos C, Bureau JM, Temmar M, Labat C, Bean K, Thomas F, Pannier B, Asmar R, Zureik M, Safar M, Guize L: Determinants of accelerated progression of arterial stiffness in normotensive subjects and in treated hypertensive subjects over a 6-year period. Circulation 2002; 105: 1202-1207.
28. Bohm M, Reil JC, Danchin N, Thoenes M, Bramlage P, Volpe M. Association of heart rate with microalbuminuria in cardiovascular risk patients: data from I-SEARCH. J Hypertens 2008; 26: 18-25.
29. Palatini P, Casiglia E, Pauletto P, Staessen J, Kaciroti N, Jukius S: Relationship of tachycardia with high blood pressure and metabolic abnormalities. Hypertension 1997; 30: 1267-1273.
30. O' Hartaigh B, Bosch JA, Carroll D, Hemming K, Pilz S, Loebroks A, Kleber ME, Grammer TB, Fisher JE, Boehm B, Marz W, Thomas NG: Evidence of a synergistic association between heart rate, inflammation, and cardiovascular mortality in patients undergoing coronary angiography. Eur Heart J 2013; 34: 932-941.
31. Zulfigar U, Jurivich DA, Singer DH: Relation of high heart rate variability to healthy longevity. Am J Cardiol 2010; 105: 1181-1185.
32. Grassi G, Vailati S, Bertinieri G, Seravalle G, Stella ML, Dell'Oro R, Mancia G: Heart rate as marker of sympathetic activity. J Hypertens 1998; 16: 1635-1639.
33. Rogowski O, Shapira I, Shirom A, Melamed S, Toker S, Berliner S: Heart rate and microinflammation in men: a relevant atherothrombotic link. Heart 2007; 93: 940-944.
34. Jouven X, Empana JP, Schwartz PJ, Desmos M, Courbon D, Ducimeltiere P: Heart rate profile during exercise as a predictor of sudden death. N Engl J Med 2005; 152: 1915-1958.
35. Jesen MT, Suadicani O, Hein HO, Gynderlberg F: Elevated resting heart rate, physical fitness and all-cause mortality: a 16-year follow-up in the Copenhagen Male Study. Heart 2013; 99: 882-887.
36. Gillman MW, Kannel WB, Belanger A, D'Agostino RB: Influence of heart rate on mortality among persons with hypertension: the Framingham Study. Am Heart J 1993; 125: 1148-1154.
37. Fox K, Borer JS, Camm J, Danchin N, Ferrari R, Sendon JLL, Steg PG, Tardif JC, Tavazzi L, Tendera M; Heart Rate Working Group: Resting heart rate in cardiovascular disease. J Am Coll Cardiol 2007; 50: 823-830.
38. Palatini P, Benetos A, Grassi G, Julius S, Kjeldsen SE, Mancia G, Narkiewicz K, Parati G, Pessina AC, Ruilope LM, Zanchetti A: Identification and management of the hypertensive patients with elevated heart rate: statement of the European Society of Hypertension consensus meeting. J Hypertens 2006; 24: 603-610.
39. Palatini P: Role of elevated hear rate in the development of cardiovascular disease in hypertension. Hypertension 2012; 58: 745-750.
40. Diaz A, Bourassa MG, Guertin MC, Tardif JC: Long-term prognostic value of resting heart rate in patients with suspected or proven coronary artery disease. Eur Heart J 2005; 26: 967-974.
41. Fox K, Ford I, Steg PG, Tendera M, Robertson M, Ferrari R; BEAUTIFUL Investigators: Heart rate as prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomized trial. Lancet 2008; 372: 817-821.
42. Kjekshus J: Comments-beta blockers: heart rate reduction a mechanism of benefit. Eur Heart J 1985; 6(suppl. A):29-30.
43. Hjalmarson A. Gilpin EA, Kjekshus J, Schieman G, Nicod P, Henning H, Ross J Jr: Influence of heart rate on mortality after acute myocardial infarction. Am J Cardiol 1990; 65: 547-553.
44. Boudoulas H: Therapeutic interventions which may improve survival in patients with coronary artery disease. Acta Cardiol 1990; 45: 477-487.
45. Beere PA, Glagov S, Zarins CK: Retarding effects of heart rate on coronary atherosclerois. Science 1984; 226: 180-184.
46. Schirmer SH, Degen A, Baumhakel M, Custodis F, Schuh L, Kohihaas M, Friedrich E, Bahlmann F, Kappl R, Maack C, Bohm M, Laufs U: Heart rate reduction by IF-channel inhibition with ivabradine restores collateral artery growth in hypercholesterolemic atherosclerosis. Eur Heart J 2011; 33: 1223-1231.
47. Borer JS, Fox K, Jailon P, Lerebours G: Antianginal and anti-ischemic effects of ivabradine, an I(f) inhibitor, in stable angina: a randomized, doubled-blind, multicentered, placebo-controlled trial. Circulation 2003; 107: 817-823.
48. Fox K, Ford I, Steg GP. Tendera M, Ferrari R; BEAUTIFUL Investigators: Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomized double-blind, placebocontrolled trial. Lancet 2008; 372: 807-816.
49. Fox K, Ford I, Steg GP, Tardif JC, Tendera M, Ferrari R; SIGNIFY Investigators: Ivabradine in stable coronary artery disease without clinical heart failure. N Engl J Med 2014; 371: 1091-1099.
50. Fox K, Komajda M, Ford I, Robertson M, Bohm M, Borer JS, Steg GS, Tavazzi L, Tendera M, Ferrari R, Swedberg K: Effect of ivabradine in patients with left-ventricular systolic dysfunction: a pooled analysis of individual patients data from BEAUTIFUL and SHIFT trials. Eur Heart J 2013; 34: 2263-2270.
51. Manz M, Reuter M, Lauck G, Omran H, Jung W: A single intravenous dose of ivabradine, a novel If inhibitor, lowers heart rate but does not depress left ventricular function in patients with left ventricular dysfunction. Cardiology 2003; 100: 149-155.
52. Ferrari R: Ivabradine: heart rate and left ventricular function. Cardiology 2014; 128: 226-230.
53. Kolloch R, Legler UF, Champion A, Cooper-DeHoff RM, Handberg E, Zhou Q, Pepine CJ: Impact of resting heart rate on outcomes in hypertensive patients with coronary artery disease: findings from the International Verapamil-SR/Trandolapril Study (INVEST). Eur Heart J 2008; 29: 1327-1334.
54. Tsika EP, Poulimenos LE, Boudoulas KD, Manolis AJ: The J-curve in arterial hypertension: fact or fallacy? Cardiology 2014; 129: 126-135.
55. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilberd EM, Shusterman NH: The effect of carvedilol on mortality and morbidity in patients with chronic heart failure. N Engl J Med 1996; 334: 1349-1355.
56. Lechat P, Hulot JS, Escolano S, et al: Heart rate and cardiac rhythm relationship with bisoptol benefit in chronic heart failure in the GIBIS II trial. Circulation 2001; 103: 1428-1433.
57. Hjalmarson A, Goldstein S, Fagerberg B, et al; MERIT-HF Study Group: Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL, Randomized Intervention Trial in Congestive Heart Failure (MERIT-II). JAMA 2000; 283: 1295-1302.
58. Dobre D, Borer JS, Fox K, Swedberg K, Adams KF, Clelard JGF, Cohen-Solal AS Chergrade M, Gueyffier FF, O'Connor CM, Fidzet M, Patak A, Pin I, Rozano G, Sebach HN, Tavazzi L, Zannad F: Heart rate: a prognostic factor and therapeutic target in chronic heart failure. The distinct roles of drugs with heart rate lowering properties. Eur J Heart Fail 2014; 10: 76-85.
59. Habal MV, Liu PP, Austin PC, Ross HJ, Newton GE, Wang X, Tu JV, Lee DS: Association of heart rate at hospital discharge with mortality and hospitalizations in patients with heart failure. Circ Heart Fail 2014; 7: 12-20.
60. Dobre D, Zannad F, Keteylan SJ, Stevens SR, Rossignol O, Kitzman DW, Landzberg J, Howlett J, Krauss WE, Ellis SJ: Association between resting heart rate, chronotropic index, and long term outcomes in patients with heart failure receiving ?-blocker therapy: data from the HF-ACTION trial. Eur Heart J 2013; 34: 2271-2280.
61. Greene SJ, Vaduganathan M, Wilcox JE, Haristein ME, Maggioni AP, Subacius H, Zannad F, Konstam MA, Chioncel O, Yancy CW, Swedberg K, Butler J, Bonow RO, Gheorghiade M; EVEREST Investigators: The prognostic significance of heart rate in patients hospitalized for heart failure with reduced ejection fraction in sinus rhythm: insight from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan) JACC Heart Fail 2013; 1: 488-496.
62. Shinbane JS, Wood MA, Jensen DN, Elenbogen KA, Fitzpatrick AP, Scheinman MM: Tachycardia induced cardiomyopathy: a review of animal models and clinical studies. J Am Coll Cardiol 1997; 29: 709-715.
63. Bohm M, Swedberg K, Komajda, Borer JS, Ford I, Dubost-Brama A, Lerebours G, Tavazzi L; SHIFT Investigators: Heart rate as a risk factor in chronic heart failure (SHIFT). The association between heart rate and outcomes in a randomized placebo-controlled trial. Lancet 2010; 376: 886-894.
64. Reil JC, Tardif JC, Ford I, Lloyd SM, O'Meara E, Komajda M, Borer JF, Tavazzi L, Swedberg K, Bohm M: Selective heart rate reduction with ivabradine unloads the left ventricle in heart failure patients. J Am Coll Cardiol 2013; 62: 1977-1985.
65. De Ferrari GM, Mazzuero A, Argesina I, et al: Favourable effects of heart rate reduction with intravenous administration of ivabradine in patients with advanced heart failure. Eur Heart Fail 2008; 10: 550-555.
66. Ekman I, Chassany O, Komajda M, Bohm M, Borer JS, Ford I, Tavazzi L, Swedberg K: Heart rate reduction with ivabradine and health related quality of life in patients with chronic heart failure: results from the SHIFT study. Eur Heart J 2011; 32: 2395-2404.
67. Tardif JC, O'Meara E, Komajda M, Bohm M, Borer JS, Ford I, Tavazzi L, Swedberg K; SHIFT Investigators: Effects of selective heart rate reduction with ivabradine on left ventricular remodeling and function: results from the SHIFT echocardiographic substudy. Eur Heart J 2011; 32: 2507-2515.
68. Dyer AR, Persky V, Stamler J, et al: Heart rate as a prognostic factor for coronary heart disease and mortality: findings in Chicago epidemiologic studies. Am J Epidemiol 1980; 112: 736-749.
69. Williams B, Lacy PS; ASCOT Investigators: Impact of heart rate on central aortic pressure and hemodynamics: analysis from the CAFE (Conduit Artery Function Evaluation) study. J Am Coll Cardiol 2009; 54: 705-713.
70. Mittleman MA, Maclure M, Tofler GH, Sherwood JB, Goldberg RJ, Muller JE: Triggering of acute myocardial infarction by heavy physical exertion. Protection against triggering by regular exertion. Determinants of Myocardial Infarction Onset Study Investigators. N Engl J Med 1993; 329: 1677-1168.
71. Tardif JC, Polikowski O, Kahan T: Efficacy of the I(f) current inhibitor ivabradine in patients with chronic stable angina receiving beta-blocker therapy: a 4-month, randomized, placebo-controlled trial. Eur Heart J 2009; 30: 540-548.
72. Borer JS, Bohm M, Ford I, Robertson M, Komajda M, Tavazzi L, Swedberg K: Efficacy and safety of ivabradine in patients with severe chronic systolic heart failure (from the SHIFT study). J Am Coll Cardiol 2014; 113: 497-503.
73. Dierckx R, Cleland JGF, Parsons S, Putzu P, Pellicori P, Dicken B, Boyalla V, Clark AL: Prescribing patterns to optimize heart failure rate: analysis of 1,000 consecutive outpatient appointments to a single heart failure clinic over a six-month period. JACC Heart Fail 2015; 3: 224-230.
74. Borer JS: Heart rate slowing by If inhibition: therapeutic utility from clinical trials. Eur Heart J 2005; 7(suppl H):H22-H28.
75. Boudoulas KD, Leier CV, Geleris P, Boudoulas H: Shortcoming of guidelines. Cardiology 2015; 130: 187-200.